HAYWARD, Calif., Oct. 4,
2016 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ:
IPXL) announced today that the Company will release its third
quarter 2016 financial results on Wednesday,
November 9, 2016, prior to the open of the U.S. financial
markets. The Company will host a conference call and live webcast
with the investment community at 8:30 a.m.,
Eastern Time on November 9,
2016.
The financial results and live webcast will be accessible
through the Investor Relations section of the Company's Web site at
http://investors.impaxlabs.com.
To access the call through a conference line, dial (877)
356-3814 (in the U.S.) and (706) 758-0033 (international callers).
The conference ID is 93578226.
A replay of the conference call will be available for seven days
shortly after the call. To access the replay, dial (855) 859-2056
(in the U.S.) and (404) 537-3406 (international callers). The
access code for the replay is 93578226.
About Impax Laboratories, Inc.
Impax Laboratories, Inc. (Impax) is a specialty
pharmaceutical company applying its formulation expertise and drug
delivery technology to the development of controlled-release and
specialty generics in addition to the development of central
nervous system disorder branded products. Impax markets its generic
products through its Impax Generics division and markets its
branded products through the Impax Specialty
Pharma division. Additionally, where strategically
appropriate, Impax develops marketing partnerships to fully
leverage its technology platform and pursues partnership
opportunities that offer alternative dosage form technologies, such
as injectables, nasal sprays, inhalers, patches, creams and
ointments. For more information, please visit the Company's Web
site at: www.impaxlabs.com.
Company Contact:
Mark
Donohue
Investor Relations and Corporate Communications
(215) 558-4526
www.impaxlabs.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/impax-to-report-third-quarter-2016-results-on-november-9-2016-300338791.html
SOURCE Impax Laboratories, Inc.